$2,200.00
We use our efficient integration-free, small molecule-based method to differentiate high-quality hematopoietic progenitor cells (HPC) from human iPSCs. The differentiated HPCs recapitulate the phenotype and functional parameters of primary and in vivo HPCs.
We provide HPCs differentiated from an integration-free, control human iPSC line (ASE-9211), reprogrammed from the fibroblasts of an African American male donor. These high-purity (>70%) cells express high levels of HPC biomarker CD34.
These iPSC-differentiated HPCs can be used as control lines to compare phenotype and functionality of patient-derived, genome-edited iPSC-derived HPCs for drug screening applications.
| Table Header | Table Header |
|---|---|
|
Age |
Neonate |
|
Gender |
Male |
|
Ethnicity |
African American |
|
Tissue source |
Dermal fibroblasts |
|
Reprogramming method |
Episomal |
|
Culture conditions |
Feeder-free |
